World Blood Banking & Blood Products Market

World Blood Banking & Blood Products Market

This report analyzes the worldwide markets for Blood Banking & Blood Products in Millions of US$. The specific product segments analyzed are Blood Components and Plasma Products (Whole Blood & Cellular Components, & Plasma Fractions), and Equipment, Blood Tests and Other Consumables (Includes blood screening and related QC function, but excludes patient diagnosis). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual forecasts are provided for each region for the period of 2001 through 2015. A ten-year historic analysis is also provided for these markets with annual market analytics. The report profiles 206 companies, including leading blood banks such as AABB, America’s Blood Centers, American Red Cross, Canadian Blood Services, CorCell Companies, Inc., Cord Blood Registry, Japan Red Cross, Lifebank Corp, National Blood Foundation, New England Cord Blood Bank, Inc., New York Blood Center, and VITA 34 AG. Some of the leading players in Blood Bank Technology & Supplies also discussed in this report include Beckman Coulter Inc., Becton Dickinson, BioMerieux SA, Caridian BCT, Inc., Chiron, CSL Behring, Daxor Corporation, Fenwal Inc., Fresenius SE, Gambro AB, Gen-Probe Incorporated, Haemonetics Corp, Hemagen Diagnostics Inc., Immucor Inc., Kawasumi Laboratories, Inc., Olympus America, Inc., PharmaStem Therapeutics, Inc., Terumo Corporation, ThermoGenesis Corp., and ZymeQuest, Inc. Leading Players discussed under the Plasma Fractionation segment include Baxter International Inc., Bio Products Laboratory, CSL Limited, CSL Bioplasma, Grifols, Kedrion, Laboratorie Francais du Fractionnement et des Biotechnologies, Octapharma, Sanquin, and Talecris Biotherapeutics. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

BLOOD BANKING & BLOOD PRODUCTS MCP-1028
A GLOBAL STRATEGIC BUSINESS REPORT


CONTENTS


I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
Blood Components and Plasma Products I-3
Whole Blood & Cellular Components I-3
WBCs I-4
RBCs I-4
Platelets I-4
Plasma Fractions I-4
Fresh Frozen Plasma I-4
Albumin Fractions I-4
Factor VIII I-4
Factor IX and Factor IX Complex I-5
Fibrin/Thrombin I-5
Equipment, Blood Tests and Consumables I-5
Automated Analyzers for Blood Analysis I-5
Blood Tests I-5
Consumables I-5


II. EXECUTIVE SUMMARY

1. Market Overview II-1
Healthcare Scares Propel the Market II-1
Blood Transfusion Worldwide: A Kaleidoscope of Stark Contrasts II-1
Worldwide Blood Banking and Blood Products Market at a Glance II-2
Current & Future Analysis II-2
Analysis by Geographic Region II-2
Analysis by Product Segment II-3
World Blood Components and Plasma Market Analysis in Units II-3
Table 1: World Recent Past, Current & Future Analysis for
Blood Components and Plasma by Region/Country - USA, Europe,
Japan, and Rest of World Markets Independently Analyzed with
Annual Consumption in Million Units for Years 2001 through
2010 (includes corresponding Graph/Chart) II-3

Table 2: World 10-Year Perspective for Blood Components and
Plasma by Region/Country - Percentage Breakdown of Volume
Consumption for USA, Europe, Japan, and Rest of World Markets
for Years 2001, 2008 & 2010 (includes corresponding
Graph/Chart) II-4
Red Blood Cells - A Key Blood Component and a Major Contributor II-5
Table 3: World Recent Past, Current & Future Analysis for
Red Blood Cells by Region/Country - USA, Europe, Japan, and
Rest of World Markets Independently Analyzed with Annual
Consumption in Million Units for Years 2001 through 2010
(includes corresponding Graph/Chart) II-5

Table 4: World 10-Year Perspective for Red Blood Cells by
Region/Country - Percentage Breakdown of Volume Consumption
for USA, Europe, Japan, and Rest of World Markets for Years
2001, 2008 & 2010 (includes corresponding Graph/Chart) II-5

2. Market Trends & Issues II-6
New Infections - A Continuous Threat II-6
Safety and Availability: The Core Issues II-6
Decontamination: A Viable Process II-7
New Processes for Safer Blood Supply II-7
Innovative Procedures Help Blood Conservation II-7
Autologous Transfusion Strapping up for High Growth II-7
Enzyme Converted Cells Set to Rule the Industry II-7
Blood Unavailability: Substitutes to the Rescue II-8
Transfusions: Hospitals Making Way for Others II-8
Computer Identification Helps Patients II-8
SARS: A Case of Mistaken Identity? II-9
Pooling: Economical HIV Testing II-9
Private Cord Blood Banking: Flying High Despite Opposition II-9
Consolidation Whittles Down Number of Market Players II-9
Table 5: Leading Players in World Market for Plasma
Fractionation (2005): Percentage Breakdown of Fractionation
Capacity for CSL Limited, Telecris, Baxter, Grifols,
Octapharma and Others (includes corresponding Graph/Chart) II-10
Automation of Blood Banking - Nearing the Efficiency Frontier? II-10
Automated Instrumentation Taking the Front Seat II-10
Table 6: World Market for Blood Bank Technology (2004):
Percentage Breakdown of Revenues by Segment - Manual Blood
Bag Systems, Automated Systems, Component Lab, Commercial
Plasma, Blood Salvage, and Pathogen Inactivation (includes
corresponding Graph/Chart) II-10

Table 7: Leading Players in the World Market for Automated
Collection of Blood Components using Apheresis Technology
(2005): Percentage Breakdown of Revenues for Gambro, Baxter,
Haemonetics, Fresenius, and Others (includes corresponding
Graph/Chart) II-11
Plasma Market: Automation Making Inroads II-11
The RBC Market - Slow to Catch Up II-11
Automation of Testing - Yet to Mature II-11
Automation to Suffice Shortage Problems II-12
How Near to the Efficiency Frontier? II-12

3. Product Overview II-13
Blood Banking and Blood Products Industry II-13
Blood Components and Plasma Products II-13
Equipment, Blood Tests and Consumables II-13
Automated Analyzers for Blood Analysis II-13
Blood Tests II-13
Consumables II-14
Blood Collection Equipment II-14
Blood Collection Monitors II-14
Blood Donor Couches II-14
Blood Processing Equipment II-14
Blood Bank Centrifuges II-14
Plasma Thawing II-14
Blood Cell Separators II-14
Blood Storage Equipment II-15
Blood Bags II-15
Platelet Agitators II-15
Blood Bank Refrigerators II-15
Blood - A Primer II-15
Ionic Structure II-15
Blood Components and their Applications II-16
Blood Constituents II-17
Plasma II-17
Red Blood Cells (RBC) II-17
Blood Count II-18
Platelets II-18
Table 8: Platelets (Leucodepleted) Issued by Select Region/
Agency (2005) (includes corresponding Graph/Chart) II-18
White Blood Cells (WBC) II-19
Derivative Products of Blood or Plasma Fractions II-19
Plasma Protein and Fractionation II-19
The Need II-19
Fresh Frozen Plasma II-20
Other Plasma Fractions II-20
Albumin Fractions II-20
Albumin Usage Rising in Profile, Wastage Worries Run Deep II-20
Immunoglobulins II-20
Table 9: Leading Countries in IVIg Usage Rates in Grams per
1000 Population (includes corresponding Graph/Chart) II-21
Hyper-Immune Immunoglobulin II-21
Factor VIII II-21
Table 10: Leading Players in World Market for Factor VIII
(2006): Percentage Breakdown of Revenues for Baxter, Bayer
(Kogenate), CSL Behring (Helixate) and Wyeth (includes
corresponding Graph/Chart) II-21
Factor IX and Factor IX Complex II-21
Fibrin/Thrombin II-22
Consumption of Blood Based on Type of Surgery/ Accident (In
Units) II-22
Table 11: World Market for Plasma Derivatives (2005):
Percentage Breakdown of Revenues by Region/Country - USA,
Europe, Asia-Pacific, Latin America, and Rest of World
(includes corresponding Graph/Chart) II-22

Table 12: World Market for Plasma Derivatives (2006):
Percentage Breakdown of Revenues by Product Type - IVIg,
Factor VIII, Albumin, Hyperimmunes, Factor IX and Others
(includes corresponding Graph/Chart) II-22
Table 13: Plasma Collection in Select Countries in Thousand
Liters (2005) (includes corresponding Graph/Chart) II-23
Recombinant Products II-23
Therapeutic Uses of Plasma Products II-23
Albumin Products II-23
Immunoglobulins II-24
Intravenous Immunoglobulin (IVIg) II-24
Normal Immunoglobulin (IMIg) II-24
CMV Immunoglobulin II-24
Hepatitis B Immunoglobulin II-24
Rh(D) Immunoglobulin II-24
Tetanus Immunoglobulin IM II-24
Zoster Immunoglobulin II-25
Plasma Derived Coagulant Products II-25
Biostate® II-25
Ceprotin® II-25
Factor VII Concentrate II-25
Factor XI Concentrates II-25
Feiba VH® Inhibitor Treatment II-25
Fibrogammin P® II-25
Monofix®-VF II-25
ProthrombinexTM-HT II-26
Thrombotrol®-VF II-26

4. Blood Collection Methods II-27
Banking the Natural Blood Resources II-27
Blood Banks II-27
Blood Banking II-27
Blood Transfusion II-27
Role of Blood Banks II-27
Blood Donor: The Epicenter of the Process II-27
Eligibility Criteria for the Donor II-28
The Basics of Blood Donation - Myths Exploded & Other Facts II-28
Table 14: Active Donors of Whole Blood and Apheresis per
1,000 of Population by Country/Agency (2004 & 2005)
(includes corresponding Graph/Chart) II-29

Table 15: Percentage Breakdown of Apheresis and Whole Blood
Donations by Country (2005) (includes corresponding
Graph/Chart) II-30
Collection Methods II-30
Blood Donation: The Process II-30
Types of Blood Donation II-30
Directed Blood Donations II-30
Autologous Blood Donation II-31
Alternative Usage of Patient’s Own Blood II-31
General Blood Donation II-31
Hemodilution II-31
Wound Drainage II-31
Cell Saver II-31
The Method II-31
Blood Salvaging II-32
Blood Collection Centers II-32
Blood Collection Management System II-32
A Historical Retrospective II-32
Blood Collection Centers II-32
Types of Blood Collection Centers II-32
Cord Blood Banks II-32
Profit Collection Centers II-33
Military Blood Banks II-33
Hospital Blood Banks II-33
Community Blood Banks II-33
Non-Profit Collection Centers II-33
Blood Processing II-34
Blood Typing II-34
Rh Blood Group System II-35
ABO Blood Group System II-35
Blood Types and their Compatibility II-35
Table 16: Occurrence of Blood Groups Worldwide (In %)
(includes corresponding Graph/Chart) II-36
Blood Test II-36
Blood Culture II-36
The Costs II-36
History of Blood Banking II-37

5. The Changing Landscape of Transfusion Technologies & Tests II-39

Blood Transfusion: A Backdrop II-39
Massive Transfusion II-39
Complications and Risks Due to Transfusion II-39
Circulatory Overload II-40
Graft Versus Host Disease (GVHD) II-40
Haemolytic Transfusion Reactions II-40
Iron Overload II-40
Bacterial Contamination II-40
Thrombophlebitis II-40
Allergic Reactions II-40
Air Embolism II-41
Hyperkalaemia II-41
Changing Role of Blood Banking Technology II-41

6. Blood Transfusion: The Process, Tests/Technologies II-42
Cross Matching II-42
Blood Donor/Recipient Screening II-42
Blood Typing II-42
Leukoreduction II-42
Leukocyte Reduction Specification Standards/Filters II-43
Coombs Test II-43

7. Alternatives to Blood Transfusion: A Real Threat to the Industry II-44

Bloodless Surgery II-44
Therapeutic Apheresis II-44
Plasmapheresis II-44
Plateletpheresis II-44
Leukapheresis II-45
Volume Expanders II-45
Colloids II-45
Albumin II-45
Dextrans II-45
Hydroxyethyl Starch II-45
Crystalloids II-45
Blood Growth Factor Therapies - Newer Alternatives to Transfusion II-46

8. Blood Substitutes II-47
Blood Substitutes Under Development by Manufacturers II-47
Synthetic Blood Manufacturers/Developers II-48
Alliance Pharmaceuticals Corp. (USA) II-48
Biopure Corporation (USA) II-48
Enzon Pharmaceuticals (USA) II-48
Hemosol Inc. (Canada) II-49
Northfield Laboratories Inc. (USA) II-49
Synthetic Blood International, Inc. (USA) II-49

9. Product Introductions/Innovations II-50
Gen-Probe Introduces APTIMA® HPV Assay II-50
Olympus AU680® Analyzer Offers an Automated HbA1c Assay II-50
Haemonetics Unveils New Plasma Collection Software II-50
Pall Unveils Acrodose™ PLus System II-50
Z-Medica Rolls Out Rapid Blood Clotting Products in the
Consumer Market II-51
Dade Behring Launches the Quadriga BeFree System II-51
Swedish Inventors Develop New Processing System II-51
Canada Invents New Method for Monitoring Blood and Blood Products II-51
Terumo Launches Improvised Bags For Safe Blood Collection II-51
Haemonetics Launches Cymbal Automated Blood Collection System II-52
Illinois Inventors Introduces New Systems to Prepare Blood
Products II-52
Abbott Unveils Two New Products for Blood Banks II-52
Cell Robotics Introduces New Lasette P 200 II-53
Beckman’s COULTER® LH 750 Hematology Analyzers Hit the Market II-53
Haemonetics Unveils MCS®+ - Improved Red Cell Collection
Technology II-53
Baxter Launches ALYX Component Collection System II-53
Grifols’ DG Gel® Revolutionizes Column Agglutination II-54
BioMérieux Introduces DAVINCI® II-54
Pall Develops Novel Blood Filtration Membrane II-54

10. Products in Pipeline & Technology Update II-55
From Clinical Trials to Clinics II-55
Cerus Receives CE Mark Approval for the Intercept Blood
System for Platelets II-55
Haemonetics Wins FDA Approval for the ACP 215 System II-55
Biomerieux’ Polycarbonate BacT/ALERT Receives US FDA Clearance II-55
Pall’s eBDS Receives Green Signal from FDA II-56
CardioPAT™ Surgical Blood Salvage System II-56
PCS® 2 - Set to Enhance Plasma Quality II-56
Dade Behring’s D-Dimer Assay Strapping up for Roll Out II-56

11. Recent Industry Activity II-57
Global Med Technologies® Acquires eDonor® II-57
Immucor Snaps Up BioArray Solutions II-57
Global Med Technologies Acquires Inlog II-57
Gen-Probe to Acquire Innogenetics II-57
ProMetic to Hold Major Share in Pathogen Removal and
Diagnostic Technologies II-58
ThermoGenesis Partners with GE Healthcare II-58
ThermoGenesis Ties Up with University of California II-58
Gambro Inks Preliminary Agreement with S.C.M S.r.l. II-58
ITL Extends Agreement with American Red Cross II-58
CSL Enters into Agreements with Héma-Québec and Canadian Blood
Services II-58
Gambro Launches Bloodline Manufacturing Plant in Czech Republic II-59
Global Med Technologies® and Mid Coast Sign a License Agreement II-59
Global Med Technologies® Inks an Agreement with FBC II-59
ZymoGenetics Obtains FDA Approval for Marketing Recothrom II-60
CellaVision Enters into a Two-Year Manufacturing Agreement
with Kitron AB II-60
VITA 34 and BKK Gruner + Jahr Sign Cooperation Agreement II-60
Haemonetics Bags FDA Clearance for eLynx II-60
Haemonetics Obtains FDA Approval for Symphony 2.0 Software II-60
Thermogenesis Receives CE Mark Approval for Marrowxpress™ II-61
Olympus PK 7300® Automated Microplate System Bags FDA Clearance II-61
ABL80 FLEX CO-OX Blood Gas Analyzer Receives FDA Clearance II-61
PK® Blood Grouping and Phenotyping Reagents Get FDA Approval II-61
Blood Banks with quality Transfusion Therapy to Come Up in
Indian Metros II-62
Haemonetics Acquires Infonalé II-62
Gambro BCT Changes its Name to Caridian BCT II-62
Terumo Acquires Salymed II-62
Fresenius Takes Over Renal Solutions II-62
PerkinElmer Completes ViaCell Acquisition II-62
Texas Cord Blood Bank Expands Cord Blood Collection Network II-63
Inverness Medical Acquires HemoSense II-63
Haemonetics Acquires Haemoscope’ Hemostasis Analyzer Business
Unit II-63
NxStage Medical Completes Medisystems Acquisition II-63
CordLife Establishes Cord Blood Bank in Indonesia II-64
Xinjiang Deyuan Begins Construction of a New Blood Product Plant II-64
Cord Blood America Acquires Curesource II-64
Grifols and Cerus Join Hands to Commercialize Cerus’ Intercept
Blood System II-64
Fresenius Kabi Signs Agreement to Acquire Kyorin Pharmaceutical II-64
Immucor and American Red Cross Ink Supply Agreement II-65
Haemonetics Signs Contract with Octapharma II-65
SFDA Revokes Drug Approval and Production Permit of Guangdong
Bioyee II-65
Immucor Obtains Clearance from FDA for Marketing Galileo Echo II-65
Novartis Receives Approval for PROCLEIX® TIGRIS® System II-65
Thermogenesis Obtains FDA Approval for Autoxpress™ II-65
CSL Receives Approval for Rhophylac® II-66
CSL Expands Haemate® P Business II-66
ViaCell to Expand ViaCord Processing Laboratory II-66
Cryobanks to Set Up a Cord Blood Bank in Thailand II-66
Grifols to Manage Four New Plasma Collection Centers in US II-66
Hualan Biological Acquires Chongqing Yituo II-66
CyGenics to Focus on Cord Blood Banking II-67
Cord Blood America Acquires CorCell II-67
Stemcyte to Establish Cord Blood Bank in India II-67
Baxter Divests Transfusion Therapies Business II-67
Cerus Obtains Approval for Intercept Blood System in Germany II-68
Cangene Obtains Health Canada Approval for Anti-Hepatitis B
Blood Product II-68
Cord Blood America Inks Marketing Agreement with MSBCBS II-68
BCCL Acquires Stake in Life Cell II-68
bioMérieux and AdvanDx Sign Distribution Agreement for Rapid
Diagnostic Tests II-68
Vita 34 International AG Expands Umbilical Cord Blood Banking
Services II-69
Data Innovations to Develop Data Capture and Reporting System
for Fenwal II-69
SunTech Medical Group Acquires Empirical Technologies II-69
Cord Blood America Acquires Cryobank II-69
Kalbe Acquires Stake in CyGenics’s Subsidiary CordLife Indonesia II-70
Cryobanks International Signs Letters of Intent with MedStem
Services II-70
Cryobanks International Opens Cord Blood Stem Cell Bank II-70
DomaniCell Initiates Family Cord Blood Banking Program in
Hospitals II-70
Cryobanks International Grants License for Cord Blood
Processing System II-71
Community Blood Center Bags Contract II-71
Wilkes Medical Center Grants License for SafeTrace Tx II-71
Biosite Collaborates with HUG Research Hospital II-71
Pliva Terminates Agreement with Mayne II-71
Mississippi Blood Services Secures Contract II-72
APL Partners with Omscan II-72
DomaniCell Receives Stem Cell Banking License II-72
ThermoGenesis Enters into an Agreement with Cord Blood Registry II-72
ZLB Enters into Plasma Deal with BCA II-72
ViaCell and Pall Secure FDA Approval for ViaCord® Collection Kit II-73
Pall Secures Contract from NBS to Supply ‘Leukotrap’
Filtration System II-73
Biotest and Sanquin to Form Joint Venture for Plasma Production II-73
Consorta Signs Partnership Agreement with GSABC II-74
Haemonetics Signs Supply Agreement with Canadian Blood Services II-74
Haemonetics Extends the Agreement with American Red Cross II-74
Novation and Abbott Enter into a Technology Agreement II-75
Olympus Redefines the Agreement with Biotest II-75
Cerus to Receive Marketing Rights over Baxter’s INTERCEPT
Blood System II-75
CyGenics to Establish a New Cord Blood Banking Company II-76
UKCBB to Establish a Modern Laboratory in UMIC’s New CTF II-76
St. John’s Medical Center Procures Wyndgate’s SafeTrace Tx II-76
Florida`s Blood Centers Acquires South Florida Blood Banks II-76
BioStem Takes Over Cryobanks International II-77
FCBS Creates a Niche for itself by designing Cord Blood Stem
Cells and Offers Public Donation Option II-77
Pall Signs Sale Agreement with Green Cross for Blood Filters II-77
TCBB Starts Collecting Donations for Cord Blood II-77
Pall Received FDA Clearance to Market New Pall Acrodose™ PL
System II-77
CordLife Singapore Receives AABB Accreditation II-78
ITL and ARC Enter into an Agreement for Blood Bank Equipment II-78
NBA and UKT Merge to Form NHSBT II-78
BioMérieux and ExonHit Extend Collaboration to Develop Blood
Diagnostics II-78
Wyndgate Signs Agreement with Cameron Hospital II-79
Daxor’s Subsidiary Wins Corporate Blood Banking Contract from
Taglich Brothers II-79
Baxter and American Red Cross Enter Into Agreement II-79
CSL Signs Agreement with National Blood Authority II-79
Chiron Finds a South African Partner for Procleix® Tigris® II-79
ThermoGenesis and BHHTI Jointly Market CryoSeal FS II-80
Baxter and Cerus Enter into a Marketing Agreement II-80
Haemonetics Signs Technology Alliance with ZLB Plasma Services II-80
BioTime Collaborates with Summit Pharmaceuticals International
Corp. II-80
SurgiLance Bags a Contract from America’s Blood Centers II-80
Florida’s Blood Centers Acquire Lake Park-based South Florida
Blood Banks II-80
Global Med Technologies’ Division Signs Agreement with
Hospital Partners of America II-81
Radiometer America and Consorta Extend Blood-Gas Products Deal II-81
Baxter's ALYX System Wins Medical Design Excellence Award II-81
Terumo Corp. Ups Stake in Blood Bag Venture II-81
Vita 34 International AG Takes over the Holdings of Corcell
and Vita 34 II-81
CSL Acquires Aventis Behring II-82
Medsurge Medical Products Corp. Buys Cryo Genomics II-82
Haemonetics’ Acquisition of Harvest Technologies Expands
Surgical Blood Salvage Portfolio II-82
Chiron Buys Prion Solutions II-82
Celmed & Gambro Tie up for GvHD Prevention System II-82
Chiron Grants NAT Licenses to LabCorp and German Red Cross II-82
Sekisui Chemical Ventures into Chinese Blood Collection Market II-83
Stratec and Biotest Partner on the Development of a Blood
Grouping Analyzer II-83
PRDT, ARC & Maco Pharma in a Strategic Alliance II-83
Pall’s Enhanced Bacterial Detection System to be Marketed by
Kawasumi II-83
Baxter and Cerus Rope in Bioone Corp for Marketing Intercept II-84
Chiron Partners with ZymeQuest II-84
Pall Corporation Signs Agreement with Haemonetics Corporation II-84
Haemonetics Corporation & Hemosystem SA in a Marketing Alliance II-84
Chiron’s Armor Strengthened with Infectio’s Rapid Bacterial
Detection Licenses II-84
Haemonetics, Braemed and Caster in a Marketing Agreement for
Cell Saver® 5 II-85
Haemonetics Obtains Marketing Licenses for Crit Scan® II-85
Lifebank Receives AABB Accreditation II-85
Bayer Divests Plasma Products Business to NPS II-85
ITL Receives FDA Clearance to Market SSK II-86
Chronix Biomedical Files Patent Approval for a New Diagnostic
Test II-86
ViaCell’s Selective Amplification™ Program Boosts Cord Blood
Banks’ Productivity II-86
CordLife Opens Second Cord Blood Banking Facility Singapore II-86
PharmaStem Inks Multiple Licensing Deals for Cord blood
Preservation Technologies II-86
Novation Bags Big Ticket Deals for Blood Products II-86

12. Focus on Select Global Players II-87
Leading Blood Banks II-87
AABB (USA) II-87
America’s Blood Centers (USA) II-87
American Red Cross (USA) II-87
Canadian Blood Services (Canada) II-88
CorCell Companies Inc. (USA) II-88
Cord Blood Registry (USA) II-88
Japan Red Cross (Japan) II-89
Lifebank Corp (Canada) II-89
National Blood Foundation (USA) II-89
New England Cord Blood Bank, Inc. (USA) II-90
New York Blood Center (USA) II-90
VITA 34 AG (Germany) II-90
Leading Players in Blood Bank Technology & Supplies II-91
Beckman Coulter Inc (USA) II-91
Becton Dickinson (USA) II-91
BioMerieux SA (France) II-91
Caridian BCT, Inc (USA) II-91
Chiron (USA) II-92
CSL Behring LLC (USA) II-92
Daxor Corporation (USA) II-93
Fenwal Inc., (USA) II-93
Fresenius SE (Germany) II-93
Gambro AB (Sweden) II-94
Gen-Probe Incorporated (USA) II-94
Haemonetics Corp., (USA) II-94
Hemagen Diagnostics Inc. (USA) II-95
Immucor Inc. (USA) II-95
Kawasumi Laboratories, Inc. (Japan) II-96
Olympus America, Inc. (USA) II-96
PharmaStem Therapeutics, Inc. (USA) II-96
Terumo Corporation (Japan) II-96
ThermoGenesis Corp. (USA) II-97
ZymeQuest, Inc. (USA) II-97
Leading Players in Plasma Fractionation II-97
Baxter International Inc. (USA) II-97
Bio Products Laboratory (UK) II-98
CSL Limited (Australia) II-98
CSL Bioplasma (Australia) II-98
Grifols (Spain) II-98
Kedrion (Italy) II-99
Laboratoire Français du Fractionnement et des Biotechnologies
(France) II-99
Octapharma (Switzerland) II-99
Sanquin (The Netherlands) II-100
Talecris Biotherapeutics (USA) II-100

13. Global Market Perspective II-101
Table 17: World Recent Past, Current & Future Analysis for
Blood Banking and Blood Products by Geographic Region - USA,
Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin
America and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2001 through
2010 (includes corresponding Graph/Chart) II-101

Table 18: World Long-term Projections for Blood Banking and
Blood Products by Geographic Region - USA, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Latin America and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-102

Table 19: World Historic Review for Blood Banking and Blood
Products by Geographic Region - USA, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Latin America and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 1991 through 2000 (includes
corresponding Graph/Chart) II-103

Table 20: World 15-Year Perspective for Blood Banking and
Blood Products by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World Markets for
Years 1998, 2008 & 2012 (includes corresponding Graph/Chart) II-104

Table 21: World Recent Past, Current & Future Analysis for
Blood Components and Plasma Products by Geographic Region -
USA, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Latin America and Rest of World Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2001
through 2010 (includes corresponding Graph/Chart) II-105

Table 22: World Long-term Projections for Blood Components and
Plasma Products by Geographic Region - USA, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Latin America and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-106

Table 23: World Historic Review for Blood Components and
Plasma Products by Geographic Region - USA, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Latin America and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 1991 through 2000 (includes
corresponding Graph/Chart) II-107

Table 24: World Recent Past, Current & Future Analysis for
Blood Components and Plasma Products by Product Group - Whole
Blood & Cellular Components, and Plasma Fractions Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2001 through 2010 (includes corresponding
Graph/Chart) II-108

Table 25: World Long-term Projections for Blood Components and
Plasma Products by Product Group - Whole Blood & Cellular
Components, and Plasma Fractions Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2011 through 2015 (includes corresponding Graph/Chart) II-108

Table 26: World Historic Review for Blood Components and
Plasma Products by Product Group - Whole Blood & Cellular
Components, and Plasma Fractions Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
1991 through 2000 (includes corresponding Graph/Chart) II-109

Table 27: World 15-Year Perspective for Blood Components and
Plasma Products by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World Markets for
Years 1998, 2008 & 2012 (includes corresponding Graph/Chart) II-110

Table 28: World 15-Year Perspective for Blood Components and
Plasma Products by Product Group - Percentage Breakdown of
Value Sales for Whole Blood & Cellular Components, and Plasma
Fractions Markets for Years 1998, 2008 & 2012 II-110

Table 29: World Recent Past, Current & Future Analysis for
Whole Blood & Cellular Components by Geographic Region - USA,
Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin
America and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2001 through
2010 (includes corresponding Graph/Chart) II-111

Table 30: World Long-term Projections for Whole Blood &
Cellular Components by Geographic Region - USA, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Latin America and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-112

Table 31: World Historic Review for Whole Blood & Cellular
Components by Geographic Region - USA, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Latin America and Rest of
World Markets Independently Analyzed with Annual Sales in US$
Million for Years 1991 through 2000 (includes corresponding
Graph/Chart) II-113

Table 32: World 15-Year Perspective for Whole Blood & Cellular
Components by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World Markets for
Years 1998, 2008 & 2012 (includes corresponding Graph/Chart) II-114

Table 33: World Recent Past, Current & Future Analysis for
Plasma Fractions by Geographic Region - USA, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Latin America and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2001 through 2010 (includes
corresponding Graph/Chart) II-115

Table 34: World Long-term Projections for Plasma Fractions by
Geographic Region - USA, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-116

Table 35: World Historic Review for Plasma Fractions by
Geographic Region - USA, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 1991 through 2000 (includes corresponding
Graph/Chart) II-117

Table 36: World 15-Year Perspective for Plasma Fractions by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Latin America and Rest of World Markets for Years 1998, 2008 &
2012 (includes corresponding Graph/Chart) II-118

Table 37: World Recent Past, Current & Future Analysis for
Equipment, Blood Tests and Other Consumables by Geographic
Region - USA, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), Latin America and Rest of World Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2001 through 2010 (includes corresponding Graph/Chart) II-119

Table 38: World Long-term Projections for Equipment, Blood
Tests and Other Consumables by Geographic Region - USA,
Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin
America and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2011 through
2015 (includes corresponding Graph/Chart) II-120

Table 39: World Historic Review for Equipment, Blood Tests and
Other Consumables by Geographic Region - USA, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Latin America and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 1991 through 2000 (includes
corresponding Graph/Chart) II-121

Table 40: World 15-Year Perspective for Equipment, Blood Tests
and Other Consumables by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Latin America and Rest of
World Markets for Years 1998, 2008 & 2012 (includes
corresponding Graph/Chart) II-122


III. MARKET

1. The United States III-1
A.Market Analysis III-1
Current and Future Analysis III-1
Market Trends III-1
US Blood Collection & Supply Profile III-1
Blood Group Distribution III-1
Table 41: US Market for Blood Banking and Blood Products:
Percentage Break up of Blood Group by Rh Factor (includes
corresponding Graph/Chart) III-2
Table 42: Percentage Break up of Rh Blood Types in the US
by Racial Group III-2
Blood Donated and Transfused Every Year III-2
Males Form the Major Chunk of Donors III-2
Cost of Blood III-3
SARS Scares: Blood Banks Feel the Heat III-3
Blood and Blood Preparations: Trade Statistics III-3
Table 43: US Blood and Blood Preparations Market (2006 &
2007): Major Import Sources by Country - Germany, UK,
Canada, Switzerland, Belgium and Others (In US$ Million)
(includes corresponding Graph/Chart) III-3

Table 44: US Blood and Blood Preparations Market (2006 &
2007): Major Export Destinations by Country - Germany,
Netherlands, UK, Switzerland, Canada and Others (In US$
Million) (includes corresponding Graph/Chart) III-4
Whole Human Blood: Export-Import Scenario in the Recent Past III-4
Table 45: US Market for Whole Human Blood (2003 & 2004):
Percentage Breakdown of Volume Exports by Country - France,
Canada, UK, Germany, Japan, Taiwan, Korea, Belgium,
Netherlands, Italy, Peru, and Others (includes
corresponding Graph/Chart) III-5

Table 46: US Market for Whole Human Blood (2003 & 2004):
Percentage Breakdown of Value Exports by Country - France,
UK, Germany, Japan, Canada, Belgium, Korea, Peru, Taiwan,
Netherlands, Italy, and Others (includes corresponding
Graph/Chart) III-6

Table 47: US Market for Whole Human Blood (2003 & 2004):
Percentage Breakdown of Volume Imports by Country - Japan,
UK, Germany, Indonesia, and Canada (includes corresponding
Graph/Chart) III-6

Table 48: US Market for Whole Human Blood 2003 & 2004):
Percentage Breakdown of Consumption of Value Imports by
Country - Japan, UK, Germany, Indonesia, and Canada
(includes corresponding Graph/Chart) III-7
US Blood Components and Plasma Market Analysis in Units III-7
Table 49: US Recent Past, Current & Future Analysis for
Blood Components and Plasma by Product Category - Red Blood
Cells (RBCs), Platelets, and Fresh Frozen Plasma Markets
Independently Analyzed with Annual Consumption in Million
Units for Years 2001 through 2010 (includes corresponding
Graph/Chart) III-7

Table 50: US 10-Year Perspective for Blood Components and
Plasma by Product Category - Percentage Breakdown of Volume
Consumption for Red Blood Cells (RBCs), Platelets, and
Fresh Frozen Plasma for Years 2001, 2008 & 2010 (includes
corresponding Graph/Chart) III-8
Regulations Control Plasma Collection Industry III-8
Product Launches/Developments III-8
Strategic Corporate Developments III-12
Select Players III-30
Blood Banks III-30
AABB III-30
America’s Blood Centers III-31
American Red Cross III-31
Blood Bank of Alaska III-32
California Cryobank III-32
Family Cord Blood Services Inc. III-32
Community Blood Bank III-33
CorCell Companies Inc. III-33
Cord Blood Registry III-33
National Blood Foundation III-33
New England Cord Blood Bank, Inc. III-34
New York Blood Center III-34
Oklahoma Blood Institute III-34
Blood Bank Technology Developers and Consumables Suppliers III-35
Beckman Coulter Inc. III-35
Becton, Dickinson and Company III-35
Caridian BCT, Inc III-35
Chiron III-36
CSL Behring LLC (USA) III-36
Daxor Corporation III-37
Fenwal Inc., III-37
Gen-Probe Incorporated III-37
Haemonetics Corp., III-38
Hemagen Diagnostics Inc. III-38
Immucor Inc. III-38
Olympus America, Inc. III-39
Pall Corporation III-39
PharmaStem Therapeutics, Inc. III-39
ThermoGenesis Corp. III-40
ViaCell, Inc. III-40
ZymeQuest, Inc. III-40
Major Plasma Fractionators III-41
Baxter International Inc. III-41
Talecris Biotherapeutics III-41
B.Market Analytics III-42
Table 51: US Recent Past, Current & Future Analysis for
Blood Banking and Blood Products by Product Group/ Segment -
Blood Components and Plasma Products (Whole Blood & Cellular
Components, and Plasma Fractions); and Equipment, Blood
Tests and Other Consumables Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2001
through 2010 (includes corresponding Graph/Chart) III-42

Table 52: US Long-term Projections for Blood Banking and
Blood Products by Product Group/Segment - Blood Components
and Plasma Products (Whole Blood & Cellular Components, and
Plasma Fractions); and Equipment, Blood Tests and Other
Consumables Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) III-42

Table 53: US Historic Review for Blood Banking and Blood
Products by Product Group/Segment - Blood Components and
Plasma Products (Whole Blood and Cellular Components, and
Plasma Fractions); and Equipment, Blood Tests and Other
Consumables Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 1991 through 2000 (includes
corresponding Graph/Chart) III-43

Table 54: US 15-Year Perspective for Blood Banking and Blood
Products by Product Group/Segment - Percentage Breakdown of
Value Sales for Blood Components and Plasma Products (Whole
Blood & Cellular Components, and Plasma Fractions); and
Equipment, Blood Tests and Other Consumables Markets for
Years 1998, 2008 & 2012 (includes corresponding Graph/Chart) III-43

2. Canada III-44
A.Market Analysis III-44
Current and Future Analysis III-44
Blood Facts III-44
Bleeding Disorders - A Major Threat III-44
The ‘CSA-Z 902-04’ - A Comprehensive Voluntary Blood Safety
Standard III-44
Blood and Blood Preparations: Import & Export Scenario III-45
Table 55: Canadian Blood and Blood Preparations Market
(2006 & 2007): Major Import Sources by Country - US, The
Netherlands, Switzerland, Belgium, Italy and Others (In US$
Million) (includes corresponding Graph/Chart) III-45

Table 56: Canadian Blood and Blood Preparations Market
(2006 & 2007): Major Export Destinations by Country - US,
France, Chile, Belgium, Germany and Others (In US$ Million)
(includes corresponding Graph/Chart) III-45
Product Launches/Developments III-46
Strategic Corporate Developments III-46
Select Players III-48
LifeBank III-48
Canadian Blood Services III-48
The Canadian Hemophilia Society (CHS) III-49
B.Market Analytics III-49
Table 57: Canadian Recent Past, Current & Future Analysis
for Blood Banking and Blood Products by Product
Group/Segment - Blood Components and Plasma Products (Whole
Blood & Cellular Components, and Plasma Fractions); and
Equipment, Blood Tests and Other Consumables Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2001 through 2010 (includes corresponding
Graph/Chart) III-49

Table 58: Canadian Long-term Projections for Blood Banking
and Blood Products by Product Group/ Segment - Blood
Components and Plasma Products (Whole Blood and Cellular
Components, and Plasma Fractions); and Equipment, Blood
Tests and Other Consumables Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart) III-50

Table 59: Canadian Historic Review for Blood Banking and
Blood Products by Product Group/Segment - Blood Components
and Plasma Products (Whole Blood & Cellular Components, and
Plasma Fractions); and Equipment, Blood Tests and Other
Consumables Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 1991 through 2000 (includes
corresponding Graph/Chart) III-50

Table 60: Canadian 15-Year Perspective for Blood Banking and
Blood Products by Product Group/Segment - Percentage
Breakdown of Value Sales for Blood Components and Plasma
Products (Whole Blood & Cellular Components, and Plasma
Fractions); and Equipment, Blood Tests and Other Consumables
Markets for Years 1998, 2008 & 2012 (includes corresponding
Graph/Chart) III-51

3. Japan III-52
A.Market Analysis III-52
Current and Future Analysis III-52
Growing Market for Fresh Frozen Plasma